B. Riley initiated coverage of Crescent Capital BDC (CCAP) with a Neutral rating and $13.50 price target Crescent has historically compared favorably to the business development company sector on credit and operating metrics, but its more recent performance “has been less compelling,” the analyst tells investors in a research note. As such, Riley finds the shares appropriately valued at current levels.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCAP:
- Ex-Dividend Date Nearing for These 10 Stocks – Week of March 29, 2026
- Crescent Capital BDC Issues New Senior Unsecured Notes
- Crescent Capital BDC Balances Rate Headwinds, Resets Outlook
- Crescent Capital BDC price target lowered to $13 from $14 at Wells Fargo
- CCAP Upcoming Earnings Report: What to Expect?